Actively Recruiting
Studying Edetate Calcium Disodium and Succimer to Manage Metals During Chemotherapy for Acute Myeloid Leukemia and Myelodysplastic Syndrome
Led by M.D. Anderson Cancer Center · Updated on 2026-09-18
58
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the effects and best dose of two drugs, edetate calcium disodium and succimer, in patients with acute myeloid leukemia AML or myelodysplastic syndrome MDS who are receiving chemotherapy. The study aims to see if these drugs help reduce metal levels in the bone marrow and blood, potentially improving disease control and response to chemotherapy. This is a phase 1 trial focusing on dose escalation and safety. Participants receive either edetate calcium disodium intravenously daily over 30 minutes for 4 doses each chemotherapy cycle or succimer taken orally daily for 8 or 21 days per cycle, along with multivitamin capsules daily. Treatment can continue for up to 6 cycles unless the disease progresses or unacceptable side effects occur. A dose expansion phase involves combination therapy with both drugs during chemotherapy. During the trial, participants undergo monitoring of metal levels in the blood and bone marrow, and assessments of treatment response, including remission rates and survival outcomes. Safety is closely observed through adverse event tracking up to 30 days after treatment. Additional exploratory studies include genetic and protein analyses. The total study duration depends on treatment cycles and follow-up assessments extending through the treatment period.
CONDITIONS
Brief Title
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
Research Team
M
Maro Ohanian
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here